ST. LOUIS PARK, Minn., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering ...

ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE) -- NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering ...

Very early results with a minimally invasive chordal replacement procedure suggest that the beating-heart, echo-guided procedure may emerge as another option for treating degenerative mitral valve ...

ST. LOUIS PARK, Minn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- NeoChord, Inc., a privately-held medical technology company, is leading the advancement of beating heart mitral valve repair in patients ...

CardioMech received strong support by investors despite challenging environment because of its potential to be a category-defining Chordal Repair technology MINNEAPOLIS, Jan. 2, 2024 /PRNewswire/ -- ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

Privately-held heart device maker NeoChord Inc. announced Monday the closing of a $25 million funding round—its largest to date—that received contributions from several out-of-state investors. The St.

MINNEAPOLIS, June 24, 2026 /PRNewswire/ -- Norway-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve chordal repair technology in Fridley, MN ...

Cardiomech AS raised $13 million in fresh capital via a convertible loan agreement that will go towards developing its transcatheter mitral valve chordal repair technology. The round was heavily ...

NeoChord, Inc. (“NeoChord”) announced on October 4, 2021 that it successfully completed a first-in-human procedure with the NeXuS Transcatheter Mitral Chordal Repair (TMVr) device NeoChord is ...